JAK2 and acute lymphoblastic leukemia: We first demonstrated significant in vivo sensitivity of two P2RY8::CRLF2/JAK2R683-mutant (DS-ALL47) and P2RY8::CRLF2/JAK2 wild-type (DS-ALL515) DS-ALL PDX models to ruxolitinib monotherapy (Fig. 6A).